BlueCross BlueShield Federal Employee Program

ERBITUX
(**cetuximab**)

Pre - PA Allowance

None

Prior-Approval Requirements

Age 18 years of age or older

Diagnoses

Patient must have **ONE** of the following:

1. Squamous cell carcinoma of the head and neck
    a. Stage III
        i. If non-nasopharyngeal site- concurrent radiation therapy
    b. Stage IV
        i. If non-nasopharyngeal site- concurrent radiation therapy and **ONE** of the following:
            1) As a single agent
            2) In combination with carboplatin and fluorouracil
            3) In combination with cisplatin with or without fluorouracil, docetaxel or paclitaxel
        ii. If nasopharyngeal site- concurrent radiation and carboplatin
2. Metastatic colorectal cancer (CRC)
    a. Patient must have **ONE** of the following:
        i. *KRAS/NRAS* wild-type gene expression as determined by FDA-approved tests **AND ONE** of the following:
            1) Used as a single agent: patient has failed oxaliplatin- and irinotecan-based chemotherapy or is intolerant to irinotecan
            2) First-line treatment: used in combination with FOLFIRI
            3) Used in combination with irinotecan: patients is refractory to irinotecan-based chemotherapy
        ii. BRAF V600E mutation as detected by an FDA-approved test
            1) Used in combination with Braftovi (encorafenib)
            2) Patient must **NOT** have wild-type BRAF CRC
            3) **NOT** used as first-line therapy
3. Locally advanced or metastatic colorectal cancer (CRC)
    a. Used in combination with Krazati (adagrasib)
    b. Patient has received prior treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy
    c. Presence of KRAS G12C mutation as determined by an FDA-approved test

4. Metastases of squamous cell skin cancer
5. Metastases of penile cancer
6. Non-small cell lung cancer (NSCLC)
    a. EGFR mutation
    b. Progressed after EGFR tyrosine kinase inhibitor therapy
    c. Used in combination with Gilotrif (afatinib)

AND the following for **ALL** indications:

a. Prescriber agrees to monitor serum electrolytes, magnesium, potassium, calcium levels, and serious infusion reactions.

Prior - Approval Limits

Duration 12 months

Prior – Approval *Renewal* Requirements

Age 18 years of age or older

Diagnoses

Patient must have **ONE** of the following:

1. Squamous cell carcinoma of the head and neck
    a. Stage III
        i. If non-nasopharyngeal site- concurrent radiation therapy
    b. Stage IV
        i. If non-nasopharyngeal site- concurrent radiation therapy and **ONE** of the following:
            1) As a single agent
            2) In combination with carboplatin and fluorouracil
            3) In combination with cisplatin with or without fluorouracil, docetaxel or paclitaxel
        ii. If nasopharyngeal site- concurrent radiation and carboplatin

2. Metastatic colorectal cancer (CRC) **AND ONE** of the following:
    a. Used as a single agent
    b. Used in combination with FOLFIRI
    c. Used in combination with irinotecan
    d. Used in combination with Braftovi encorafenib

3. Locally advanced or metastatic colorectal cancer (CRC) **AND** the following:
    a. Used in combination with Krazati (adagrasib)
4. Metastases of squamous cell skin cancer

5. Metastases of penile cancer
6. Non-small cell lung cancer (NSCLC)
    a. Used in combination with Gilotrif (afatinib)

AND ALL of the following for **ALL** indications:

a. **NO** disease progression or unacceptable toxicity
b. Prescriber agrees to monitor serum electrolytes, magnesium, potassium, and calcium levels

Prior – Approval *Renewal* Limits

Same as above